Activating RET Mutations Promotes Osteoblastic Bone Metastases in Medullary Thyroid Cancer

Area of Science:

• Oncology
• Endocrinology
• Bone Biology

Background:

• Bone metastases significantly increase mortality in medullary thyroid cancer (MTC).
• The mechanisms driving MTC bone metastasis and associated osteoblastic changes remain largely unknown.

Purpose of the Study:

• To elucidate the mechanisms by which MTC cells induce osteoblastic bone lesions.
• To investigate the role of the RET signaling pathway in MTC bone metastasis.
• To identify potential biomarkers for MTC bone metastases.

Main Methods:

• Utilized patient-derived MTC cell lines (RET C634W and RET M918T mutants).
• Established a mouse model of MTC bone metastasis.
• Assessed osteoblast and osteoclast differentiation markers.
• Measured circulating levels of osteoprotegerin (OPG).
• Investigated the effects of RET knockdown and pharmacological RET inhibition.

Main Results:

• MTC cells promote an osteoblastic phenotype by reducing bone resorption.
• Activated RET signaling increases osteoprotegerin (OPG) expression, inhibiting osteoclast differentiation.
• RET inhibition reduced MTC tumor burden and osteoblastic lesions in vivo.
• Elevated circulating OPG levels in MTC patients correlated with bone metastases and poor survival.
• Multi-kinase inhibitor treatment lowered circulating OPG levels.

Conclusions:

• The RET signaling pathway is critically involved in MTC-induced osteoblastic bone formation.
• Increased OPG expression due to RET activation contributes to the development of bone metastases.
• Circulating OPG serves as a potential biomarker for MTC bone metastases and prognosis.
• Targeting RET may offer a therapeutic strategy for MTC bone disease.